Biocryst Pharmaceuticals (BCRX) Amortization of Deferred Charges (2011 - 2023)

Biocryst Pharmaceuticals (BCRX) has reported Amortization of Deferred Charges for 13 consecutive years, with $22.4 million the latest figure, recorded in Q3 2023.

• For the quarter ending Q3 2023, Amortization of Deferred Charges rose 21.51% year-over-year to $22.4 million; the trailing twelve-month figure through Sep 2023 stood at $110.1 million (up 51.04% YoY), and the FY2022 full-year result was $98.9 million, up 82.49% from the prior year.
• Amortization of Deferred Charges eased to $22.4 million in Q3 2023 per BCRX's latest filing, from $23.7 million in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $43.8 million in Q4 2022 and bottomed at $255000.0 in Q1 2019.
• Historically, Amortization of Deferred Charges has averaged $12.4 million across 5 years, with a median of $12.7 million in 2021.
• The sharpest annual moves came in 2021 and 2023: Amortization of Deferred Charges surged 3515.75% in 2021, then advanced 6.38% in 2023.
• Over 5 years, Amortization of Deferred Charges stood at $342000.0 in 2019, then surged by 561.99% to $2.3 million in 2020, then soared by 684.63% to $17.8 million in 2021, then surged by 146.56% to $43.8 million in 2022, then sank by 48.97% to $22.4 million in 2023.
• According to Business Quant data, Amortization of Deferred Charges over the past three periods registered $22.4 million, $23.7 million, and $20.2 million for Q3 2023, Q2 2023, and Q1 2023 respectively.